Repurposing FDA-Approved Drugs for Eumycetoma Treatment: Homology Modeling and Computational Screening of CYP51 Inhibitors
International Journal of Molecular Sciences · 01.01.2025 · 26 (1) · 315
DOI: 10.3390/ijms26010315 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 01.01.2025. Verfasst von Magdi Awadalla Mohamed und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, College of Pharmacy, Jouf University, Sakaka 72388, Saudi Arabia. Hauptthemen laut MEDLINE: Mycetoma, Antifungal Agents, Drug Repositioning, Madurella. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deanship of Graduate Studies and Scientific Research, Jouf University, Saudi Arabia, Deanship of Graduate Studies and Scientific Research at Jouf University.
Abstract (Originalsprache)
Eumycetoma, a chronic fungal infection caused by Madurella mycetomatis, is a neglected tropical disease characterized by tumor-like growths that can lead to permanent disability and deformities if untreated. Predominantly affecting regions in Africa, South America, and Asia, it imposes significant physical, social, and economic burdens. Current treatments, including antifungal drugs like itraconazole, often show variable efficacy, with severe cases necessitating surgical intervention or amputation. Drug discovery for eumycetoma faces challenges due to limited understanding of the disease’s molecular mechanisms and the lack of 3D structures for key targets such as Madurella mycetomatis CYP51, a well-known target for azoles’ antifungal agents. To address these challenges, this study employed computational approaches, including homology modeling, virtual screening, free energy calculations, and molecular dynamics simulations, to repurpose FDA-approved drugs as potential treatments for eumycetoma targeting Madurella mycetomatis CYP51. To this end, a library of 2619 FDA-approved drugs was screened, identifying three promising candidates: montelukast, vilanterol, and lidoflazine. These compounds demonstrated favorable binding affinities, strong interactions with critical residues of the homology model of Madurella mycetomatis CYP51, and stability in molecular dynamics simulations, offering potential for further investigation as effective therapeutic options for eumycetoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Chemistry, College of Pharmacy, Jouf University, Sakaka 72388, Saudi Arabia.
- Pharmacy Program, Wad Medani College of Medical Sciences and Technology, Wad Medani 21111, Gezira, Sudan.
- Department of Pharmaceutics, College of Pharmacy, Jouf University, Sakaka 72388, Saudi Arabia.
ORCID-Profile: Magdi Awadalla Mohamed, Mohamed Khalid Alhaj Awadalla, Malik Suliman Mohamed, Tilal Elsaman, Eyman Mohamed Eltayib
Förderung
- Deanship of Graduate Studies and Scientific Research, Jouf University, Saudi Arabia
- Deanship of Graduate Studies and Scientific Research at Jouf University
Zitieren
APA
Mohamed, M. A., Awadalla, M. K. A., Mohamed, M. S., Elsaman, T., & Eltayib, E. M. (2025). Repurposing FDA-Approved Drugs for Eumycetoma Treatment: Homology Modeling and Computational Screening of CYP51 Inhibitors. International Journal of Molecular Sciences, 26(1), 315. https://doi.org/10.3390/ijms26010315
Vancouver
Mohamed MA, Awadalla MKA, Mohamed MS, Elsaman T, Eltayib EM. Repurposing FDA-Approved Drugs for Eumycetoma Treatment: Homology Modeling and Computational Screening of CYP51 Inhibitors. International Journal of Molecular Sciences. 2025;26(1):315. doi:10.3390/ijms26010315
BibTeX
@article{Mohamed2025,
author = {Mohamed, Magdi Awadalla and Awadalla, Mohamed Khalid Alhaj and Mohamed, Malik Suliman and Elsaman, Tilal and Eltayib, Eyman Mohamed},
title = {Repurposing FDA-Approved Drugs for Eumycetoma Treatment: Homology Modeling and Computational Screening of CYP51 Inhibitors},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {1},
pages = {315},
doi = {10.3390/ijms26010315}
}
EUVIMED